Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Capital Expenditures: 2016-2024

Historic Capital Expenditures for Whitehawk Therapeutics (WHWK) over the last 9 years, with Dec 2024 value amounting to $1.7 million.

  • Whitehawk Therapeutics' Capital Expenditures fell 99.82% to $1,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $926,000, marking a year-over-year decrease of 71.01%. This contributed to the annual value of $1.7 million for FY2024, which is 58.36% down from last year.
  • Per Whitehawk Therapeutics' latest filing, its Capital Expenditures stood at $1.7 million for FY2024, which was down 58.36% from $4.0 million recorded in FY2023.
  • Whitehawk Therapeutics' Capital Expenditures' 5-year high stood at $4.0 million during FY2023, with a 5-year trough of $19,025 in FY2020.
  • Over the past 3 years, Whitehawk Therapeutics' median Capital Expenditures value was $1.7 million (recorded in 2024), while the average stood at $2.0 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Capital Expenditures crashed by 91.97% in 2020, and later skyrocketed by 865.22% in 2022.
  • Yearly analysis of 5 years shows Whitehawk Therapeutics' Capital Expenditures stood at $19,025 in 2020, then soared by 141.79% to $46,000 in 2021, then skyrocketed by 865.22% to $444,000 in 2022, then spiked by 794.59% to $4.0 million in 2023, then plummeted by 58.36% to $1.7 million in 2024.